兆科眼科-B(06622.HK)香港公开发售获56倍认购上限定价16.8港元/股

格隆汇2021-04-28

格隆汇 4 月 28日丨兆科眼科-B(06622.HK)发布公告，公司全球发售约1.236亿股股份，其中香港发售股份4942.7万股，国际发售股份7414.05万股，另有15%超额配股权；发售价厘定为每股股份16.80港元，每手买卖单位500股；高盛及Jefferies为联席保荐人，预期股份将于2021年4月29日于联交所主板挂牌上市。根据国际发售初步提呈发售的发售股份已获超额认购，相当于国际发售...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

MartinDong
2021-04-28
MartinDong
打了不一定中，中了不一定涨，费用必须得出，完美

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2130373700?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/f73e1c908efc5972b5b6e484e19b0d22","is_english":false,"pubTime":"2021-04-28 06:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2130373700","market":"hk","top_or_hot":-1,"title":"兆科眼科-B(06622.HK)香港公开发售获56倍认购 上限定价16.8港元/股","media":"格隆汇","content":"<div>\n<p>格隆汇 4 月 28日丨兆科眼科-B(06622.HK)发布公告，公司全球发售约1.236亿股股份，其中香港发售股份4942.7万股，国际发售股份7414.05万股，另有15%超额配股权；发售价厘定为每股股份16.80港元，每手买卖单位500股；高盛及Jefferies为联席保荐人，预期股份将于2021年4月29日于联交所主板挂牌上市。根据国际发售初步提呈发售的发售股份已获超额认购，相当于国际发售...</p>\n\n<a href=\"https://www.gelonghui.com/news/detail.html?id=517116\">网页链接</a>\n\n</div>\n","source":"stock_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>兆科眼科-B(06622.HK)香港公开发售获56倍认购 上限定价16.8港元/股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n兆科眼科-B(06622.HK)香港公开发售获56倍认购 上限定价16.8港元/股\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-28 06:32 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/news/detail.html?id=517116><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇 4 月 28日丨兆科眼科-B(06622.HK)发布公告，公司全球发售约1.236亿股股份，其中香港发售股份4942.7万股，国际发售股份7414.05万股，另有15%超额配股权；发售价厘定为每股股份16.80港元，每手买卖单位500股；高盛及Jefferies为联席保荐人，预期股份将于2021年4月29日于联交所主板挂牌上市。根据国际发售初步提呈发售的发售股份已获超额认购，相当于国际发售...</p>\n\n<a href=\"https://www.gelonghui.com/news/detail.html?id=517116\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06622","symbol_name":"兆科眼科-B","start_time":0,"source_url":"https://www.gelonghui.com/news/detail.html?id=517116","article_id":"2130373700","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/f73e1c908efc5972b5b6e484e19b0d22"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2130373700","pubTimestamp":1619562753,"sourceInfo":{"source_id":"stock_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"根据香港公开发售提呈发售的发售股份接获大量超额认购。已合共接获111,183份有效申请，认购合共6.99亿股香港发售股份，相当于香港公开发售项下初步可供认购股份总数的约56倍。倘超额配股权获悉数行使，按发售价每股股份16.80港元计算，公司将就将予配发及发行的1853.5万股额外股份收取额外所得款项净额约2.974亿港元。","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06622":"兆科眼科-B"},"translate_title":"Zhaoke Ophthalmology-B (06622. HK) Hong Kong Public Offering Won 56 Times Subscription Limit Priced at HK $16.8/share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1},"content_text":"格隆汇 4 月 28日丨兆科眼科-B(06622.HK)发布公告，公司全球发售约1.236亿股股份，其中香港发售股份4942.7万股，国际发售股份7414.05万股，另有15%超额配股权；发售价厘定为每股股份16.80港元，每手买卖单位500股；高盛及Jefferies为联席保荐人，预期股份将于2021年4月29日于联交所主板挂牌上市。根据国际发售初步提呈发售的发售股份已获超额认购，相当于国际发售项下初步可供认购的股份总数的约5.3倍以上。根据香港公开发售提呈发售的发售股份接获大量超额认购。已合共接获111,183份有效申请，认购合共6.99亿股香港发售股份，相当于香港公开发售项下初步可供认购股份总数的约56倍。按发售价每股股份16.80港元，以及根据与基石投资者订立的基石投资协议，基石投资者已认购2546.1万股发售股份，相当于公司紧随全球发售完成后已发行股份总数约4.76%及全球发售项下发售股份数目的约20.60%，在各情况下均假设超额配股权未获行使。根据发售价每股股份16.80港元，公司自全球发售收取的所得款项净额估计约为19.416亿港元。公司拟将该等所得款项净额约32.0%用于核心产品的临床开发及商业化；约46.0%为集团的其他在研候选药物的持续研发活动及商业化提供资金；约7.0%为位于南沙的生产设施进行生产线扩张，以筹备未来年度的产品上市；约5.0%为集团的业务开发活动及在研药物的扩展提供资金；及10.0%用于营运资金及其他一般企业用途。倘超额配股权获悉数行使，按发售价每股股份16.80港元计算，公司将就将予配发及发行的1853.5万股额外股份收取额外所得款项净额约2.974亿港元。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":377711874,"gmtCreate":1619565358098,"gmtModify":1619565358098,"author":{"id":"3578612275669733","authorId":"3578612275669733","name":"MartinDong","avatar":"https://static.tigerbbs.com/b8c13063dcef5989116536785d8207f4","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"打了不一定中，中了不一定涨，费用必须得出，完美","listText":"打了不一定中，中了不一定涨，费用必须得出，完美","text":"打了不一定中，中了不一定涨，费用必须得出，完美","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/377711874","repostId":2130373700,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2130373700"}

兆科眼科-B(06622.HK)香港公开发售获56倍认购 上限定价16.8港元/股

精彩评论

兆科眼科-B(06622.HK)香港公开发售获56倍认购上限定价16.8港元/股